GTC Biotherapeutics, Inc. ("GTC", NASDAQ: GTCB) announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present on Tuesday, February 9, 2010 at 8:30 a.m. during the 12th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf-Astoria in New York, New York from February 8-9, 2010.
The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation.
About GTC Biotherapeutics
GTC Biotherapeutics develops, supplies and commercializes therapeutic proteins produced through transgenic animal technology. ATryn®, GTC's recombinant human antithrombin, has been approved for use in the United States and Europe. ATryn is the first and only therapeutic product produced in transgenic animals to be approved anywhere in the world. Building upon the 2009 FDA approval of ATryn®, GTC is collaborating with its US commercialization partner, Lundbeck Inc., to develop a protocol for a pivotal study of patients with acquired antithrombin deficiencies in cardiac surgery. GTC aims to initiate a clinical trial in this indication in the second half of 2010. In addition to ATryn, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa and IX, which are being developed for the treatment of patients with hemophilia, and recombinant alpha-fetoprotein, which is being developed for the treatment of Myasthenia Gravis and Multiple Sclerosis. GTC plans to advance its human recombinant factor VIIa program into a Phase I clinical study in the first half of 2010 and its alpha-fetoprotein program into a Phase II study in Myasthenia Gravis in the second half of 2010 after securing a partner for that program. GTC is also developing a portfolio of monoclonal antibodies for use as follow-on biologics. The portfolio includes antibodies targeting HER2, EGFR and TNF, which currently address markets with aggregate sales in excess of $16 billion, as well as a CD20 antibody with enhanced ADCC (antibody-dependent cell-mediated cytotoxicity). Production animals for these programs are in development, and are already established for CD20 and HER2 monoclonal antibodies. In 2010, GTC plans to characterize each of these transgenically-derived antibodies as they become available and to initiate non-clinical studies.
GTC's intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enable cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
Contacts:
GTC Biotherapeutics, Inc.
John B. Green, 508-370-5279
Senior
Vice President & Chief Financial Officer
jack.green@gtc-bio.com
